Iambic Therapeutics, Inc. (IAM)

NASDAQ: IAM · Real-Time Price · USD

14.67

-1.13 (-7.15%)

At close: Oct 22, 2026, 4:00 PM EDT

14.30

-0.37 (-2.52%)

Pre-market: Oct 23, 2026, 5:05 AM EDT

Iambic Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	18.25	9.43	1.19
Revenue Growth	-	689.45%	-
Cost of Revenue	101.74	77.53	45.7
Gross Profit	-83.49	-68.1	-44.5
Selling, General & Admin	16.69	14.25	9.38
Operating Expenses	16.69	14.25	9.38
Operating Income	-100.19	-82.35	-53.88
Interest Expense	-0.01	-0.02	-0.01
Interest & Investment Income	6.07	5.21	6.04
Other Non Operating Income (Expenses)	-0.03	-0.06	-
EBT Excluding Unusual Items	-94.17	-77.22	-47.84
Gain (Loss) on Sale of Assets	-0.03	-0.03	-
Pretax Income	-94.2	-77.25	-47.84
Income Tax Expense	0.05	0.05	0.03
Net Income	-94.25	-77.3	-47.88
Net Income to Common	-94.25	-77.3	-47.88
Net Income Growth	-	-	-
Shares Outstanding (Basic)	22	22	21
Shares Outstanding (Diluted)	22	22	21
Shares Change	-	0.93%	-
EPS (Basic)	-4.27	-3.57	-2.23
EPS (Diluted)	-4.27	-3.57	-2.23
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-68.17	-60.1	-34.27
Free Cash Flow Per Share	-3.09	-2.78	-1.60
Operating Margin	-548.93%	-873.65%	-4512.31%
Profit Margin	-516.39%	-820.02%	-4009.80%
Free Cash Flow Margin	-373.50%	-637.63%	-2869.93%
EBITDA	-98.81	-81.13	-52.82
D&A For EBITDA	1.38	1.23	1.06
EBIT	-100.19	-82.35	-53.88

SEC Filings: 10-K · 10-Q